At a glance
- Originator Pfizer
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 08 May 1998 New profile
- 08 May 1998 Discontinued-Preclinical for Asthma in USA (Unknown route)